Biophytis SA ALBPS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ALBPS is a good fit for your portfolio.
News
Trading Information
- Previous Close Price
- €0.00
- Day Range
- €0.00–0.00
- 52-Week Range
- €0.00–0.04
- Bid/Ask
- €0.00 / €0.00
- Market Cap
- €2.75 Mil
- Volume/Avg
- 12.5 Mil / 23.1 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Biophytis SA is a France-based biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Its drug candidate BIO101, is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 24
- Website
- https://www.biophytis.com
Valuation
|
Metric
|
ALBPS
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ALBPS
|
|---|---|
Quick Ratio | 0.70 |
Current Ratio | 0.72 |
Interest Coverage | −14.56 |
Quick Ratio
ALBPS
Profitability
|
Metric
|
ALBPS
|
|---|---|
Return on Assets (Normalized) | −83.74% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −207.99% |
Return on Assets
ALBPS
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Kbvkqfsf | Fzhc | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pmssxtwd | Lpwwrq | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mfcxlhwkd | Bsjdws | $98.1 Bil | |
MRNA
| Moderna Inc | Dgzxcxygb | Pylk | $39.1 Bil | |
ARGX
| argenx SE ADR | Mkvdftq | Fqmk | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Wjqqvvyw | Pkjd | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Bcmlcyr | Bcypzrb | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vplrlsvb | Vbbypp | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Svnkmzjwv | Gchlfl | $12.5 Bil | |
INCY
| Incyte Corp | Hsdznpbd | Bkmryt | $11.9 Bil |